CHAPEL HILL, N.C., Jul 23, 2001 /PRNewswire/ -- POZEN Inc. (Nasdaq:
POZN), a pharmaceutical development company with a portfolio of product
candidates for the treatment of migraine, today announced it plans to conduct a
conference call following the release of financial results for the second
quarter ended June 30, 2001. The company will release earnings before the market
opens on Thursday, July 26, 2001. John R. Plachetka, Pharm.D., POZEN's chairman,
president and chief executive officer, and Matthew E. Czajkowski, chief
financial officer, will host the conference call the same day at 11:00 a.m.
Eastern Daylight Time.
The conference call will be simulcast live on the Internet, and can be accessed
by logging on to www.streetevents.com . A replay will be available at this site,
as well as on the Investor Relations section of the company's website,
www.pozen.com , for seven days.
North Carolina-based POZEN Inc. is a pharmaceutical development company
committed to building a portfolio of products with significant commercial
potential in select therapeutic areas. The company's initial focus is migraine,
where it has built a robust portfolio of four product candidates through a
combination of innovation and in-licensing. The company's common stock is traded
on The Nasdaq Stock Market under the symbol "POZN."
POZEN is on the Internet at www.pozen.com .
Chief Financial Officer, of POZEN
Kathy Brunson of FRB Weber Shandwick